摘要:
Compounds of general formula (I), wherein R4 and R5 stand for hydrogen atom or form together an 1,3-butadienyl group, optionally substituted by a methylenedioxy group or one or more straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, hydroxy group or halogen atom; are strong adenosine A3 receptor ligands preferably antagonists.
摘要翻译:通式(I)的化合物,其中R 4和R 5表示氢原子或一起形成1,3-丁二烯基,任选被亚甲二氧基取代或 一个或多个直链或支链C 1-4烷基,直链或支链C 1-4烷氧基,羟基或卤素原子; 是强的腺苷A 3 N 3受体配体优选拮抗剂。
摘要:
The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containings them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and (III) and to the preparation thereof.
摘要翻译:本发明涉及通式(I)的腺苷A 3 N 3受体配体,其中优选为拮抗剂,以及它们的盐,溶剂合物和异构体,并且药物组合物将它们包含在使用中 的通式(I)化合物及其盐,溶剂合物和异构体制备通式(I)化合物及其盐,溶剂合物和异构体,此外还涉及一般的新的中间体 式(II)和(III)及其制备方法。